



Editor

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.270

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2015 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission. ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorial

- 631** When gout goes to the heart: does gout equal a cardiovascular disease risk factor?
J A Singh

Recommendation

- 635** Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever
G Giancane, N M Ter Haar, N Wulffraat, S J Vastert, K Barron, V Hentgen, T Kallinich, H Ozdogan, J Anton, P Brogan, L Cantarini, J Frenkel, C Galeotti, M Gattorno, G Grateau, M Hofer, I Kone-Paut, J Kummerle-Deschner, H J Lachmann, A Simon, E Demirkaya, B Feldman, Y Uziel, S Ozen

Clinical and epidemiological research

- 642** Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink
L E Clarson, S L Hider, J Belcher, C Heneghan, E Roddy, C D Mallen
- 648** Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?
J K Eriksson, K Johansson, J Askling, M Neovius
- 655** High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission
E G Araujo, S Finzel, M Englbrecht, D A Schreiber, F Faustini, A Hueber, K Nas, J Rech, G Schett

- 661** Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study
C-F Kuo, M J Grainge, C Mallen, W Zhang, M Doherty

- 668** Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis
E E A Arts, C Popa, A A Den Broeder, A G Semb, T Toms, G D Kitas, P L van Riel, J Franssen

- 675** Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice
A Lanias, M Boers, J Nuevo

- 682** Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: trait or state?
T Neogi, L Frey-Law, J Scholz, J Niu, L Arendt-Nielsen, C Woolf, M Nevitt, L Bradley, D T Felson, for the Multicenter Osteoarthritis (MOST) Study

- 689** Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort
F Costantino, A Talpin, R Said-Nahal, M Goldberg, J Henny, G Chiochia, H-J Garchon, M Zins, M Breban

- 694** Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
I B McInnes, L Thompson, J T Giles, J M Bathon, J E Salmon, A D Beaulieu, C E Codding, T H Carlson, C Delles, J S Lee, N Sattar

- 703** Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis
X Jin, J R Beguerie, W Zhang, L Blizzard, P Otahal, G Jones, C Ding

- 711** Association between childhood overweight measures and adulthood knee pain, stiffness and dysfunction: a 25-year cohort study
B Antony, G Jones, A Venn, F Cicuttini, L March, L Blizzard, T Dwyer, M Cross, C Ding

- 718** Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study
B Möller, M Pruijm, S Adler, A Scherer, P M Villiger, A Finckh, on behalf of the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, CH-8048 Zurich, Switzerland

- 724** Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort
B Combe, I Logeart, M C Belkacemi, S Dautou, T Schaeverbeke, J P Daurès, M Dougados

- 730** Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
P Moinzadeh, E Aberer, K Ahmadi-Simab, N Blank, J H W Distler, G Fierlbeck, E Genth, C Guenther, R Hein, J Henes, L Herich, I Herrgott, I Koetter, A Kreuter, T Krieg, K Kuhn, H-M Lorenz, F Meier, I Melchers, H Mensing, U Mueller-Ladner, C Pfeiffer, G Riemekasten, M Sárdy, M Schmalzing, C Sunderkoetter, L Susok, I H Tarner, P Vaith, M Worn, G Wozel, G Zeidler, N Hunzelmann, and all participating DNSS centers

- 738** Evolution of cost structures in rheumatoid arthritis over the past decade
D Huscher, T Mittendorf, U von Hinüber, I Köter, G Hoese, A Pfäfflin, S Bischoff, A Zink, for the German Collaborative Arthritis Centres

- 746** Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort
A Moltó, S Paternotte, D van der Heijde, P Claudepierre, M Rudwaleit, M Dougados

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



- 752** Disability and not osteoarthritis predicts cardiovascular disease: a prospective population-based cohort study
T A Hoeven, M J G Leening, P J Bindels, M Castaño-Bejancourt, J B van Meurs, O H Franco, M Kavousi, A Hofman, M A Ikram, J C M Witteman, S M Bierma-Zeinstra

- 757** Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
A Deodhar, J Braun, R D Inman, D van der Heijde, Y Zhou, S Xu, C Han, B Hsu

Basic and translational research

- 762** Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis
M T Maehlen, I C Olsen, B K Andreassen, M K Viken, X Jiang, L Alfredsson, H Källberg, B Brynedal, F Kurreeman, N Doha, R Toes, A Zhemakova, J Gutierrez-Achury, P I W de Bakker, J Martin, M Teruel, M A Gonzalez-Gay, L Rodríguez-Rodríguez, A Balsa, T Uhlig, T K Kvien, B A Lie

- 769** Mesenchymal stem cell therapy in proteoglycan induced arthritis
J F Swart, S de Roock, F M Hofhuis, H Rozemuller, T van den Broek, P Moerer, F Broere, F van Wijk, W Kuis, B J Prakken, A C M Marrens, N M Wulffraat

- 778** Dysregulated CD4⁺ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr^{-/-} mice
A J Wilhelm, J P Rhoads, N S Wade, A S Major

- 786** Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals
N Dalbeth, B Pool, O M Shaw, J L Harper, P Tan, C Franklin, M E House, J Cornish, D Naot

Letter

- 791** Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
J Y Humrich, C von Spee-Mayer, E Siegert, T Alexander, F Hiepe, A Radbruch, G-R Burmester, G Riemekasten

Correction

- 792** Correction

Electronic pages

Correspondence

- e31** Lymphocytic focus score as a prognostic tool
A P Risselada, M de Hair, A A Kruize, J W J Bijlsma, J A G van Roon

- e32** Persistent expression of CXCR5 on plasmablasts in IgG4-related disease
S Koarada, S Tashiro, Y Tokuda, Y Ono, Y Sadanaga, R Suematsu, N Ono, A Ohta, Y Tada